Trading Analysis Report: RXRX
- Analysis date: 2026-06-01
- Processed decision: Hold
- Price Target: 5.50
I. Analyst Team Reports
Market Analyst
Market Report
Recursion Pharmaceuticals (RXRX) traded at $3.59 on May 29, 2026. The local yfinance snapshot showed a 52-week range of $2.77-$7.18, a 50-day average of $3.28, and a 200-day average of $4.27.
The stock is still in a weak trend. yfinance showed a -14.1% one-year return and a -14.5% YTD return, with the latest price below the 200-day average.
RXRX fits the AI queue as a clinical-stage TechBio company using the Recursion OS, an AI-native platform integrating biology, chemistry, clinical development, proprietary multimodal data, purpose-built AI models, and automated laboratories.
Market read: Hold with a $5.50 target. The target is below yfinance mean and median analyst targets of $6.64 and $6.00, reflecting platform upside but high clinical and cash-burn risk.
Sentiment Analyst
Sentiment Report
Sentiment is balanced after Q1 2026.
The positive side is cash runway and pipeline progress. Cash, cash equivalents, and restricted cash were $665.2 million at March 31, 2026, and management reiterated runway into early 2028 without additional financing.
Clinical updates were constructive. REC-1245 showed early safety, predictable pharmacokinetics, target engagement, and no dose-limiting toxicities observed to date. REC-4881 showed Phase 2 FAP proof-of-concept efficacy, and REC-4539 dosed its first patient in Phase 1.
The negative side is that Q1 2026 revenue was only $6.5 million, down from $14.7 million in Q1 2025, and net loss remained large at $117.5 million.
Sentiment read: Hold. The platform story is intact, but investors still need clinical proof and disciplined burn.
News Analyst
News Report
The May 6, 2026 Q1 2026 release is the key current news item.
Recursion reiterated 2026 guidance of less than $390 million of operational cash burn and said runway extends into early 2028. Q1 2026 cash operating expense was $85.1 million, down from $120.2 million in Q1 2025.
Pipeline milestones are the core catalyst path. REC-4881 has FDA engagement underway with a regulatory update expected in 2H26. REC-1245 additional Phase 1 dose escalation data are expected in 2H26. Several other wholly owned programs have 2026-2027 updates.
Partnered discovery remains important. Recursion said Sanofi, Roche, and Genentech partnered programs continue to advance, with more than $500 million in milestone and upfront payments achieved to date.
News read: RXRX is an AI-biotech execution story where cash discipline and clinical milestones matter more than near-term revenue.
Fundamentals Analyst
Fundamentals Report
Fundamentals show a strong cash position but continued clinical-stage losses.
Q1 2026 revenue was $6.5 million, down from $14.7 million in Q1 2025. R&D expense fell to $87.9 million from $129.6 million, and G&A expense fell to $34.6 million from $54.7 million.
Net loss improved to $117.5 million from $202.5 million, and net cash used in operating activities improved to $81.1 million from $132.0 million.
Cash, cash equivalents, and restricted cash were $665.2 million at quarter-end. yfinance showed market cap of approximately $1.91 billion, enterprise value of approximately $1.32 billion, total revenue of approximately $66.4 million, price/sales of 28.7x, total cash of approximately $654.5 million, and total debt of approximately $72.4 million.
Fundamental read: the balance sheet is adequate for the next milestone cycle, but valuation depends on clinical and partnership outcomes.
II. Research Team Decision
Bull Researcher
Bull Research
The bull case is that Recursion has one of the more mature AI-native drug discovery operating systems in public markets.
The company is not just selling AI software; it is using Recursion OS to advance its own and partnered clinical pipeline. REC-1245, REC-4881, and REC-4539 show the platform is generating clinical-stage assets.
Cash runway into early 2028 gives Recursion time to reach multiple readouts without immediate financing. Operating cash use improved substantially year over year, with Q1 2026 net cash used in operating activities down to $81.1 million.
Partnered programs with Sanofi, Roche, and Genentech provide validation and potential non-dilutive milestone inflows. Recursion reported more than $500 million in milestone and upfront payments achieved to date.
Bull conclusion: if 2026-2027 clinical readouts validate the platform, RXRX can re-rate from depressed levels.
Bear Researcher
Bear Research
The bear case is that RXRX remains a clinical-stage biotech with high burn and no product revenue.
Q1 2026 revenue fell to $6.5 million, while net loss was still $117.5 million. yfinance showed price/sales of 28.7x and operating margin of negative 1985.6%.
The stock is below its 200-day average and down 14.5% YTD, showing that investors remain cautious despite AI excitement.
Risks include clinical trial failure, regulatory uncertainty, long development timelines, partnership milestone timing, revenue volatility from collaboration accounting, cash burn, future dilution, competition in AI drug discovery, and technology-platform translation risk.
Bear conclusion: Recursion still has to prove that AI-generated candidates can create durable clinical and commercial value.
Research Manager
Research Manager Synthesis
The bull case is cash runway, operating discipline, maturing AI-native platform proof points, and multiple upcoming clinical milestones.
The bear case is revenue decline, large net losses, biotech binary risk, and high valuation relative to collaboration revenue.
The correct conclusion is Hold with upside. The $5.50 target is above the latest $3.59 price but below yfinance analyst targets, recognizing upside to milestones while avoiding a full platform re-rating before clinical proof.
Synthesis: assign Hold with a $5.50 target.
III. Trading Team Plan
Trader
Trader View
RXRX is above its $3.28 50-day average but below its $4.27 200-day average. The 52-week high is $7.18, so recovery potential exists, but trend confirmation is incomplete.
Upside trigger: favorable REC-4881 regulatory update, additional REC-1245 dose escalation data, partnered milestones, cash burn below guidance, or broader AI-biotech sentiment improvement.
Downside trigger: clinical setbacks, delayed FDA feedback, higher cash burn, revenue weakness, financing concern, or a break below the 52-week low of $2.77.
Trading plan: Hold with a $5.50 6-12 month target and reassess after 2H26 clinical/regulatory updates.
IV. Risk Management Team Decision
Aggressive Analyst
Aggressive Risk View
Aggressive investors can hold RXRX as a speculative AI-biotech platform.
The upside is tied to clinical proof from REC-4881, REC-1245, and other platform-derived programs. The cash runway into early 2028 reduces near-term financing pressure.
Aggressive conclusion: Hold to speculative Buy only for investors comfortable with biotech volatility.
Conservative Analyst
Conservative Risk View
Conservative investors should wait for stronger clinical validation.
Recursion has cash and a differentiated AI platform, but it is still losing more than $100 million per quarter and does not have product revenue.
Conservative conclusion: Hold or avoid new purchases until clinical proof improves.
Neutral Analyst
Neutral Risk View
The neutral view is Hold.
RXRX has credible AI-drug-discovery optionality and runway into early 2028, but the business still depends on clinical outcomes that are uncertain. A $5.50 target leaves upside without assuming platform success is already proven.
Neutral conclusion: Hold with a $5.50 target.
V. Portfolio Manager Decision
Portfolio Manager
Portfolio Manager Decision
Rating: Hold Price Target: 5.50
Horizon: 6-12 months Current Price Reference: $3.59 on 2026-05-29
Recursion Pharmaceuticals is rated Hold. It is included in the AI queue because it is a clinical-stage TechBio company using Recursion OS, an AI-native drug discovery and development platform that integrates biology, chemistry, clinical development, proprietary multimodal data, purpose-built AI models, and automated laboratories.
The latest major financial update is Q1 2026 results. Cash, cash equivalents, and restricted cash were $665.2 million as of March 31, 2026, compared with $753.9 million at December 31, 2025. Management said runway extends into early 2028 without additional financing.
Q1 2026 revenue was $6.5 million, compared with $14.7 million in Q1 2025. R&D expense decreased to $87.9 million from $129.6 million, and G&A expense decreased to $34.6 million from $54.7 million. Net loss improved to $117.5 million from $202.5 million, and net cash used in operating activities improved to $81.1 million from $132.0 million.
Pipeline progress is the main reason to keep the rating constructive. REC-1245 early clinical data in solid tumors showed a well-tolerated safety profile, predictable dose-dependent pharmacokinetics, target engagement, and no dose-limiting toxicities observed to date. REC-4881 Phase 2 FAP proof-of-concept data showed a median 43% reduction in polyp burden at Week 13 and 53% at Week 25 after a treatment break, with FDA engagement underway and an update expected in 2H26. REC-4539 dosed its first patient in Phase 1 in April 2026.
Partnered discovery remains important. Recursion said Sanofi, Roche, and Genentech programs continue to advance, with over $500 million in milestone and upfront payments achieved to date.
yfinance showed a latest price of $3.59, market cap of approximately $1.91 billion, enterprise value of approximately $1.32 billion, 52-week range of $2.77-$7.18, total revenue of approximately $66.4 million, price/sales of 28.7x, total cash of approximately $654.5 million, total debt of approximately $72.4 million, mean analyst target of $6.64, and median analyst target of $6.00.
The main risks are clinical trial failure, regulatory uncertainty, long development timelines, partnership milestone timing, revenue volatility from collaboration accounting, cash burn, future dilution, competition in AI drug discovery, and technology-platform translation risk.
The $5.50 target reflects cash runway, cost discipline, and multiple 2026-2027 milestones, but it stays below analyst targets until Recursion shows stronger clinical validation and clearer partnership economics.